Jump to start of content

Complete requirements by 12/31/19 to avoid a change in certification status Expand/Collapse the ABIM alert.

Sign in to your Physician Portal to view any remaining requirements for the year. Not completing these requirements by 12/31/19 could result in a change to your certification status.

Breadcrumb trail:

Medical Oncology Board Exam Committee

Expand All | Collapse All

Pamela N. Munster, MD, Chair

Pamela N. Munster, MDDr. Munster, who is board certified in Internal Medicine and Medical Oncology, is Professor in Residence at the University of California, San Francisco, where she is also the Director of Early Phase Clinical Trials Program at the Helen Diller Family Comprehensive Cancer Center and Program Leader of Developmental Therapeutics. She is the co-Leader of the BRCA Center.

She served at Memorial Sloan Kettering Cancer Center as a faculty member in the breast cancer program before joining the Division of Breast Oncology and Experimental Therapeutics Program at Moffitt Cancer Center and Research Institute, Tampa, Florida. Dr. Munster led the group as the Scientific Director of Breast Research and co-Chair of the Phase I Program at Moffitt for six years prior to joining the University of California, San Francisco.

Her basic laboratory research interests are in the area of developing novel targeted therapy for the treatment of treatment resistant cancer and their integration into current treatment strategies. Dr. Munster's research interest involves basic research studies on epigenetic modification of DNA repair and therapy resistance. Her laboratory is involved in several projects testing HDAC inhibitors reverse hormone therapy resistance in breast cancer and to reengage the immune defense. Dr. Munster's clinical research interests are in the area of early anti-tumor drug development with focus on drugs that target the mTOR, P13k pathways and the epigenetic regulation of immune response to therapy. In addition to her interest in drug development, Dr. Munster has a special interest in the germline cancer mutations.

Dr. Munster has published in numerous scientific journals and has given lectures on topics such as the management of metastatic breast cancer, breast cancer receptors, clinical trials and translational research. She serves as Chair of the American Board of Internal Medicine Medical Oncology Board Exam Committee.

Dr. Munster received her medical degree from the University of Bern, Switzerland; completed her residency in internal medicine at Indiana University Medical Center then moved to Memorial Sloan Kettering Cancer Center, New York, for her oncology and hematology fellowship.

As of January 2017, Dr. Munster reported the following external relationships:

Funding for clinical trial expenses, staff and salary support, paid to the University of California, San Francisco, from the following companies:

  • Amgen
  • AstraZeneca
  • BioMarin Pharmaceutical
  • Bristol-Myers Squibb
  • Calithera Biosciences
  • Celgene
  • Cleave Biosciences
  • Clovis Oncology
  • Corcept Therapeutics
  • Genentech
  • GlaxoSmithKline
  • Merck & Co.
  • Nektar Therapeutics
  • Novartis
  • OncoMed Pharmaceuticals
  • Roche
  • Sanofi Pasteur

Work funded by educational grants from industry, paid to University of California-San Francisco, from the following companies:

  • Dr. Munster receives fellow lecture support from multiple, unknown companies.

Deborah K. Armstrong, MD

Deborah K. Armstrong, MDDr. Armstrong is Professor of Oncology and of Gynecology and Obstetrics at the Johns Hopkins University School of Medicine. She is board certified in Internal Medicine and Medical Oncology and is a member of the American Board of Internal Medicine Medical Oncology Board Exam Committee.

Previously, Dr. Armstrong chaired the Oncology Drugs Advisory Committee for the US Food & Drug Administration. She was a Principal Investigator for the Gynecologic Oncology Group (now NRG Oncology), serving on Ovarian Cancer, Medical Oncology and Phase I committees. She has participated as a scientific reviewer for National Cancer Institute (NCI), Department of Defense, National Comprehensive Cancer Network and for the Stand Up to Cancer Ovarian Cancer Dream Team award, among others.

Dr. Armstrong is a member of the Board of Directors of the Society of Gynecologic Oncology. She co-chairs the Ovarian Cancer Task Force for the NCI. She is a representative of Johns Hopkins to the National Cooperative Cancer Network serving as co-Chair of the ovarian cancer panel. She directs the gynecologic oncology clinical trials program at the Johns Hopkins Kimmel Cancer Center and the breast and ovarian cancer genetic counseling service that identifies patients at risk for cancer and recommends strategies for cancer screening and prevention.

Dr. Armstrong was awarded a Komen Foundation Fellowship, a Young Investigator Award from American Society of Clinical Oncology, a Career Development Award from the American Cancer Society, the Ladies Home Journal Breakthrough Achievement Award, the Rosalind Franklin Award for Excellence in Ovarian Cancer Research and the Johns Hopkins Department of Medicine Osler Housestaff Teaching Award.

Dr. Armstrong received a bachelor's degree in bacteriology from the University of California at Berkeley then attended the George Washington University School of Medicine and was elected to Alpha Omega Alpha. Dr. Armstrong trained in internal medicine at the University of Pittsburgh and served as Chief Medical Resident before completing medical oncology fellowship at the Johns Hopkins Oncology Center.

As of January 2017, Dr. Armstrong reported the following external relationships:

Funding for clinical trial expenses, salary support and staff, paid to Johns Hopkins University, from the following companies:

  • AstraZeneca, for two ovarian cancer trials.
  • Clovis Oncology, for two ovarian cancer trials.

Service on a research-related expert panel or advisory board for the following company, with compensation for travel expenses and honoraria:

  • Eviti, to provide guidance for evidence-based oncology care.

Work as an author or editor for the following company, with compensation as listed below:

  • UpToDate, receiving compensation as an editor for ovarian cancer topics.

Dr. Armstrong serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Society of Clinical Oncology, 2017 Program Committee Member, receiving compensation for travel.
  • Society of Gynecologic Oncology, Board of Directors and Co-Chair of Program Committee, receiving compensation for travel.

Olatoyosi M. Odenike, MD

Olatoyosi M. Odenike, MDDr. Odenike, a board certified medical oncologist, is an Associate Professor of Medicine at the University of Chicago. Dr. Odenike's clinical research and medical practice is focused on myeloid malignancies, including acute and chronic leukemias, myelodysplastic syndromes and chronic myeloproliferative neoplasms. She has a particular interest in new drug development in these diseases.

Prior to joining the faculty at the University of Chicago, Dr. Odenike worked as an Attending Physician at Roseland Community hospital, a medically underserved community on the South Side of Chicago.

Dr. Odenike currently serves as member of the American Board of Internal Medicine Medical Oncology Board Exam Committee and Medical Oncology Specialty Board. She is co-Director of the University of Chicago Phase II Consortium and is a member of the Alliance Leukemia Core Committee. She is co-Director of the University of Chicago Phase II Consortium and is a member of the Alliance Leukemia Core Committee. Additionally, she has served on various professional committees including American Society of Clinical Oncology (ASCO) Scientific Program Committee for which she also served as a Track Leader, ASCO Cancer Communications Committee and the Best of ASCO Program Committee, and she has served as Chair of Educational Programs for both ASCO and the American Society of Hematology (ASH). She is also a member of the ASH Consult a Colleague Program. She has served in various editorial capacities and review committees including the Conquer Cancer Foundation of ASCO grant review committee, ASCO International Innovation Grant review subcommittee and currently serves as a member of the Aplastic Anemia/MDS International Foundation Medical Advisory Board. In addition, Dr. Odenike serves on the Molecular and Cellular Hematology National Institutes of Health Study Section. She is the recipient of an ASCO Career Development Award and was listed in Best Doctors in America as well as Castle Connolly's Top Doctors.

Dr. Odenike received her pre-medical training at the University of Ife, Nigeria, and her medical degree from the University of Ibadan, Nigeria. She completed her residency training in internal medicine and pediatrics at the University

As of January 2017, Dr. Odenike reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Chicago, from the following companies:

  • Astex Pharmaceuticals, receiving funding for a Phase I/II study on patients with myelodysplastic syndromes.
  • Gilead Sciences, receiving funding for a Phase III study on patients with bone marrow disorders.
  • MEI Pharma, receiving funding for a Phase II study on patients with newly diagnosed acute myeloid leukemia.
  • NS Pharma, receiving funding for a Phase I/II trial of patients with bone marrow disorders.

Dipti Patel-Donnelly, MD

Dipti Patel-Donnelly, MDDr. Patel-Donnelly, a board certified internist, medical oncologist and hematologist, is a managing partner at Virginia Cancer Specialists, which is a large multi-disciplinary private practice in Northern Virginia. She has been the co-Director of the Fairfax Stem Cell Transplant Program since 2009. Focusing on a special interest in hematologic malignancies, brain tumors and stem cell transplant, Dr. Patel-Donnelly has become highly involved in local tumor boards and currently serves as Section Chief of Hematology/Oncology at Inova Fairfax Hospital and holds a Hematology/Oncology Faculty Clerkship appointment at Virginia Commonwealth University.

Dr. Patel-Donnelly holds memberships and appointments in multiple organizations. She is a member of the American Board of Internal Medicine Medical Oncology Board Exam Committee. She is also a member of the American Medical Association, the American Society of Clinical Oncology, the American Society of Hematology and the Medical Society of Virginia. Dr. Patel-Donnelly has received multiple awards and honors that include the Leukemia and Lymphoma Society's “Relentless for a Cure” award, Harvard Partners in Excellence Award, Excellence in Teaching Awards, National Institutes of Health Research Fellowship, National Association for the Self-Empoyed Achievement Scholarship and Distinguished Honors and Independent Research in Biochemistry.

Dr. Patel-Donnelly has been consistently named as a Top Doctor in publications such as Northern Virginia Magazine and Washingtonian Magazine. Additionally, she has been listed as a Castle Connolly Mid-Atlantic Top Doctor and a Washington Post Super Doctor. She is a published author and has spoken both at local educational events and in news interviews.

Dr. Patel-Donnelly completed her fellowship in medical oncology and hematology at the Dana-Farber Cancer Institute/Brigham and Women's Hospital/Massachusetts General Hospital at Harvard Medical School. Dr. Patel-Donnelly received her medical degree and completed her internal medicine internship and residency from the Mount Sinai School of Medicine in New York, New York, and she is a magna cum laude graduate in biochemistry with honors and independent research from Binghamton University in Binghamton, New York.

As of January 2017, Dr. Patel-Donnelly reported the following external relationships:

Funding for clinical trial expenses, paid to Virginia Cancer Specialists, from the following companies:

  • Dr. Patel-Donnelly receives funding from ADC Therapeutics, Ariad Pharmaceuticals, Astellas, AstraZeneca, Boston Biomedical, Clovis, EMD Serono, Gilead Sciences, Incyte, MedImmune, Novartis, OncoMed, Merck & Co., and Roche, to support trials on solid tumors and hematologic malignancies.

Suresh S. Ramalingam, MD

Suresh S. Ramalingam, MDDr. Ramalingam is Professor of Hematology and Medical Oncology and the Assistant Dean for Cancer Research at the Emory University School of Medicine in Atlanta, Georgia. He is also the Roberto C. Goizueta Chair for Cancer Research and the Deputy Director of the Winship Cancer Institute of Emory University. He is board certified in both Internal Medicine and Medical Oncology.

Before joining Emory in 2007, Dr Ramalingam served as an Assistant Professor of Medicine at the University of Pittsburgh.

He is a member of the American Board of Internal Medicine Medical Oncology Board Exam Committee. He serves as the Chair of the ECOG-ACRIN Thoracic Malignancies Committee. He also serves on the editorial boards of leading cancer journals. Dr. Ramalingam is the recipient of several awards, including the James R. Eckman Award for Excellence in Teaching from the Department of Hematology and Medical Oncology, Emory University, and the Distinguished Cancer Scholar Award, Georgia Cancer Coalition. In addition, he is a recipient of the ASCO Career Development Award (2006–2009), the ECOG Young Investigator Award, and the NCI Clinical Investigators Team Leadership Award (2010-12).

Dr. Ramalingam's research interests include development of novel anti-cancer agents and evaluation of methods to individualize therapies for patients. He has conducted several clinical trials with molecularly targeted agents in the treatment of small cell and non-small cell lung cancer. He has published more than 200 original manuscripts, review articles, editorials and book chapters.

Dr. Ramalingam received his medical degree at Kilpauk Medical College, Madras, India. He completed his residency in Internal Medicine at Wayne State University, Detroit, Michigan, where he also served as Chief Medical Resident. He then completed a fellowship in Hematology and Medical Oncology at the University of Pittsburgh Medical Center, Pittsburgh, Pennyslvania.

As of July 2017, Dr. Ramalingam reported the following external relationships:

Funding for clinical trial expenses, salary support and staff, paid to Emory University, from the following companies:

  • Amgen, for a Phase 1 study of an anti-c-fms monoclonal antibody.
  • AstraZeneca, for a study of an EGFR inhibitor in non-small cell lung cancer.
  • Bristol-Myers Squibb, for a Phase 2 clinical trial of immunotherapy in advanced non-small cell lung cancer.
  • Pfizer, for a Phase 1 study of a novel immunotherapy combination in non-small cell lung cancer.

Service on a research-related expert panel or advisory board, receiving reimbursement for travel expenses and honoraria from the following company:

  • AstraZeneca, for a scientific advisory board to provide input on the development of EGFR inhibitors in lung cancer.

Industry-supported continuing medical education supported by the following, with reimbursement for travel expenses and honoraria:

  • PRIME, continuing medical education symposium speaker.

Work as an author or editor for following companies, with compensation as listed:

  • American Cancer Society, receiving compensation as an editor for chest disease topics for Cancer.
  • UpToDate, receiving compensation as an author.

Dr. Ramalingam serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Society of Clinical Oncology, Chair of Professional Development Committee, receiving reimbursement for travel expenses.
  • International Association for Study of Lung Cancer (IASLC), Past Chair of Education Committee, without compensation.

Manish A. Shah, MD

Manish A Shah, the Bartlett Family Associate Professor of Gastrointestinal Oncology, is recognized as an excellent clinical and translational investigator focusing on drug development and advancing the care of gastrointestinal malignancies. He received a BES in Biomedical Engineering from Johns Hopkins University; MD from the Harvard/MIT Health Sciences and Training program. He completed his residency in Internal Medicine at Duke Medical Center (Durham, NC), and completed his training in Oncology at Memorial Sloan Kettering / Weill Cornell Medicine, where he was chief fellow.

He has published over 100 peer-reviewed articles and has received numerous peer-reviewed funding awards. HIs research focuses on drug development and understanding mechanisms of resistance to therapy in Gastrointestinal Malignancies. Presently, his academic titles include Chief, Solid Tumor Oncology Service; Director, Gastrointestinal Oncology Program at Weill Cornell Medicine and Co-Director, Center for Advanced Digestive Care, New York Presbyterian Hospital.

As of August 2018, Dr. Shah reported the following external relationships:

Funding for clinical trial expenses, salary support and staff, paid to Weill Cornell Medicine from the following companies:

  • Boston Biomedical, for a study on colorectal cancer, receiving funding for clinical trial expenses and staff.
  • Merck, for three cancer studies, receiving funding for clinical trial expenses, salary support and staff.
  • Oncolys Biopharma, for a study of IIT study of novel oncolytic adenovirus + pembrolizumab, receiving funding for clinical trial expenses, salary support and staff.

Service on data and safety monitoring boards for the following companies, with compensation for travel expenses and honoraria:

  • Boston Biomedical, for a study on pancreatic cancer.

Hussein Tawbi, MD

Dr. Hussein Tawbi is Associate Professor of Medical Oncology, Investigational Cancer Therapeutics, and Director of Melanoma Clinical Research and Early Drug Development at the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center. Dr. Tawbi joined MD Anderson in 2015 and in addition to being a melanoma clinician, he develops and conducts multiple clinical trials with translational endpoints in melanoma, sarcoma, and immunotherapy. His role at MD Anderson includes providing the vision and direction of clinical translational research at the Department of Melanoma Medical Oncology and enhance the operations of the clinical research staff.

Dr. Tawbi obtained his MD in 2001 from the American University of Beirut, Beirut, Lebanon. Dr. Tawbi completed his training in Internal Medicine and Hematology/Oncology at the University of Pittsburgh and joined the faculty ranks at the University of Pittsburgh as an Assistant Professor in 2007 and was promoted to Associate Professor in 2014. His clinical training was coupled with formal instruction in Clinical and Translational Research that culminated in a PhD degree in Clinical and Translational Science in 2011. Dr. Tawbi joined the University of Texas MD Anderson Cancer Center as Associate Professor in the Departments of Melanoma Medical Oncology and Investigational Cancer Therapeutics in November 2015, and recently appointed Director of Melanoma Clinical Research and Early Drug Development.

As of October 2018, Dr. Tawbi reported the following external relationships:

Funding for clinical trial expenses, salary support and staff, paid to The University of Texas MD Anderson Cancer Center, from the following companies:

  • Bristol-Myers Squibb, for a Phase II trial of ipilimumab and nivolumab in melanoma brain metastases; for a Phase II trial of nivolumab and dabrafenib and trametinib in patients with advanced melanoma; and for a Phase II/III trial of nivolumab and relatlimab in advanced melanoma; receiving funding for staff, expenses, and salary support.
  • Merck, for a Phase II trial of pembrolizumab and oral azacitidine in patients with melanoma and for a Phase II trial of pembrolizumab and GSK2636771 in patients with melanoma and PTEN loss; receiving funding for staff, expenses, and salary support.
  • Celgene, for a Phase II trial of pembrolizumab and oral azacitidine in patients with melanoma, receiving funding for staff, expenses, and salary support.
  • Genentech, for a Phase II trial of bevacizumab and atezolizumab in patients with melanoma brain metastases, receiving funding for staff, expenses, and salary support.

David Vaughn, MD

David Vaughn, MDDr. Vaughn, board certified in Internal Medicine and Medical Oncology, is the Genitourinary Medical Oncology Professor at the Abramson Cancer Center of the University of Pennsylvania. He is also Associate Chief for Clinical Affairs in the Hematology/Oncology Division.

He is a medical oncologist with expertise in the management of patients with bladder, prostate and testicular cancers. Dr. Vaughn's clinical research is focused on development of new treatments for patient with genitourinary cancer as well as the late effects of treatment in long term survivors of testicular cancer. He is the former Chair of the American Board of Internal Medicine Medical Oncology Self-Assessment Committee and now serves as a member of the ABIM Medical Oncology Board Exam Committee.

Dr. Vaughn received his medical degree from Harvard Medical School (1987), completed his internship (1988) and residency training (1990) at New York Hospital Cornell Medical Center and fellowship training at the Hospital of the University of Pennsylvania (1993).

As of January 2017, Dr. Vaughn reported the following external relationships:

Work as an author or editor for following company, with compensation as listed:

  • UpToDate, receiving compensation for authorship on section on testicular cancer survivors.

Lori J. Wirth, MD

Lori J. Wirth, MDDr. Wirth is the Medical Director of the Head and Neck Oncology Program at Massachusetts General Hospital, and an Associate Professor of Medicine at Harvard Medical School. Before joining Mass General in 2008, Dr. Wirth was on staff at the Dana-Farber Cancer Institute. She is board certified in Medical Oncology.

Dr. Wirth is a member of the American Board of Internal Medicine Medical Oncology Board Exam Committee. She currently serves as the Chairperson of the International Thyroid Oncology Program and sits on the National Comprehensive Cancer Network's Thyroid Carcinoma Guidelines Panel. She is also a member of the Dana-Farber/Harvard Cancer Center Scientific Review Committee. She has previously served on the Dana-Farber/Harvard Cancer Center Institutional Review Board and the National Cancer Institute's Head and Neck Cancer Steering Committee Recurrent/Metastatic Disease Task Force, and has recently served on the American Joint Committee on Cancer's Endocrine Expert Panel.

Dr. Wirth received her bachelor's degree from Brown University and medical degree from Columbia University's College of Physicians and Surgeons. She completed her internal medicine residency at New York Presbyterian Medical Center-Columbia Presbyterian, and completed a three-year fellowship in the Dana-Farber/Partners CancerCare Hematology/Oncology Program.

As of July 2017, Dr. Wirth reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Massachusetts General Hospital, from the following companies:

  • AstraZeneca, for a study of selumetinib in thyroid cancer and for a study of 5-azacytadine, durvalumab, tremilimumab for recurrent squamous cell carcinoma of the head and neck, receiving funding for clinical trial expenses and staff.
  • Bayer, for an observational study of thyroid cancer, receiving funding for clinical research staff.
  • Eisai, for a study of lenvatinib in thyroid cancer and in a combination Phase I trial, receiving funding for clinical trial expenses and staff.
  • Merck, for a Phase Ib trial with pembrolizumab, receiving funding for clinical trial expenses and staff.

Service on a research-related expert panel or advisory board, receiving honoraria, from the following company:

  • Blueprint Medicine, for service on an advisory board for a RET inhibitor.
  • Loxo Oncology, for service on an advisory board for a RET inhibitor.